3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
16
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
6
Melanoma
6
Breast Neoplasms
6
Carcinoma, Renal Cell
5
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Ovarian Neoplasms
2
Neoplasms
2
Liver Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Adenocarcinoma of Lung
2
Adenocarcinoma Of Esophagus
2
Adenocarcinoma
2
Uveal Melanoma
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Interventions
pembrolizumab
3
Trastuzumab
2
Irinotecan
2
Drug Therapy
2
Cisplatin
2
Capecitabine
2
tivozanib
1
tipifarnib
1
spartalizumab
1
seribantumab
1
pertuzumab
1
entinostat
1
atezolizumab
1
Thalidomide
1
Ritonavir
1
Quality of Life
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Molecular Diagnostic Techniques
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Itraconazole
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Injections, Subcutaneous
1
Immunotherapy
1
Ifosfamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
spartalizumab
×
Breast
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts